C-CJQTMAIA
telomere targeting, immuno-oncology, small molecule
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CJQT
C-CJQTC-CJQTtelomere targeting, immuno-oncology, small molecule
0-100 chain-logic scale · 15 dimensions · scored on public evidence
MAIA telomere targeting, immuno-oncology, small molecule
MAIA is a targeted therapy, immuno-oncology company focused on first-in-class drugs with novel mechanisms of action for cancer. Its lead program is ateganosine (THIO), a direct telomere-targeting agent in clinical development for telomerase-positive cancer cells, including NSCLC. MAIA is also developing second-generation telomere-targeting agents.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
MAIA — Near-term readout · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic